Clinical Trials for Mesothelioma Patients: Novartis LBH589

Read about a current clinical trial being conducted to study the effects of Novartis LBH589 for patients who have been diagnosed with mesothelioma. Please note: This information is provided by Weitz & Luxenberg for informational purposes only. For additional information, contact Novartis at 1-800-340-6843.

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

This study is currently recruiting participants.

Information provided by Novartis

Study Summary

Brief Title: Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Official Title: A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Malignant Pleural Mesothelioma

Summary: This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney